Consensus Outlook: Multiple Sclerosis
Over the next five years, the global multiple sclerosis (MS) market is set to grow from $14.4 billion in 2012 to $18.3 billion in 2017. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.
Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:
Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:
- An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance
- A detailed forecast data analysis spreadsheet model comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017
- Timely event-driven market forecast report and data analysis updates over the next 12 months
1. FORECAST DATA MODEL (EXCEL)
Tabs:
Market size
Product sales
Company forecast
Mechanism of action
Future Events
2. FORECAST ANALYSIS REPORT (PDF)
Contents:
FirstWord Analysis Highlights
Research Methodology
Multiple Sclerosis Marketplace
Key Multiple Sclerosis Developers
Multiple Sclerosis Class Dynamics
Tecfidera (dimethyl fumarate; Biogen) forecast
Aubagio (teriflunomide; Sanofi) forecast
Gilenya (fingolimod; Novartis Mitsubishi Tanabe) forecast
Tysabri (natalizumab; Biogen) forecast
Copaxone (glatiramer acetate; Teva) forecast
Avonex (interferon beta-1a; Biogen) forecast
Betaseron (interferon beta-1b; Bayer) forecast
Rebif (interferon beta-1a; Merck Serono) forecast
Extavia (interferon beta-1b; Novartis) forecast
Lemtrada (alemtuzumab; Genzyme/Sanofi) forecast
Laquinimod (Teva/Active Biotech) forecast
Daclizumab HYP (Biogen/AbbVie) forecast
Ocrelizumab (Biogen/Roche/Biogen) forecast
Tabs:
Market size
Product sales
Company forecast
Mechanism of action
Future Events
2. FORECAST ANALYSIS REPORT (PDF)
Contents:
FirstWord Analysis Highlights
Research Methodology
Multiple Sclerosis Marketplace
Key Multiple Sclerosis Developers
Multiple Sclerosis Class Dynamics
Tecfidera (dimethyl fumarate; Biogen) forecast
Aubagio (teriflunomide; Sanofi) forecast
Gilenya (fingolimod; Novartis Mitsubishi Tanabe) forecast
Tysabri (natalizumab; Biogen) forecast
Copaxone (glatiramer acetate; Teva) forecast
Avonex (interferon beta-1a; Biogen) forecast
Betaseron (interferon beta-1b; Bayer) forecast
Rebif (interferon beta-1a; Merck Serono) forecast
Extavia (interferon beta-1b; Novartis) forecast
Lemtrada (alemtuzumab; Genzyme/Sanofi) forecast
Laquinimod (Teva/Active Biotech) forecast
Daclizumab HYP (Biogen/AbbVie) forecast
Ocrelizumab (Biogen/Roche/Biogen) forecast
